Genentech licenses NovImmune's NI1401
Roche's Genentech Inc. has licensed exclusive rights to NovImmune SA's (MAbs for inflammation and immune disorders) NI1401, an anti-IL-17 fully human MAb, as well as access to back-up antibodies.
- Large Molecule
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.